Patents by Inventor Philippe Buchy

Philippe Buchy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
    Patent number: 11034730
    Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: June 15, 2021
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DU CAMBODGE
    Inventors: Frederic Tangy, Anavaj Sakuntabhai, Etienne Simon-Loriere, Claude Roth, Philippe Buchy
  • DENGUE VIRUS CHIMERIC POLYEPITOPE COMPOSED OF FRAGMENTS OF NON-STRUCTURAL PROTEINS AND ITS USE IN AN IMMUNOGENIC COMPOSITION AGAINST DENGUE VIRUS INFECTION
    Publication number: 20190300578
    Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
    Type: Application
    Filed: March 21, 2019
    Publication date: October 3, 2019
    Inventors: Frederic TANGY, Anavaj SHAKUNTABAI, Etienne SIMON-LORIERE, Claude ROTH, Philippe BUCHY
  • Dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection
    Patent number: 10316066
    Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: June 11, 2019
    Assignees: INSTITUT PASTEUR, INSTITUT PASTEUR DU CAMBODGE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Tangy, Anavaj Shakuntabai, Etienne Simon-Loriere, Claude Roth, Philippe Buchy
  • A DENGUE VIRUS CHIMERIC POLYEPITOPE COMPOSED OF FRAGMENTS OF NON-STRUCTURAL PROTEINS AND ITS USE IN AN IMMUNOGENIC COMPOSITION AGAINST DENGUE VIRUS INFECTION
    Publication number: 20170158740
    Abstract: The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors consisting of recombinant measles virus (MV) particles. The present invention also relates to the use of the recombinant MV particles, in particular under the form of a composition or of a vaccine, for the prevention and/or treatment of a dengue virus infection.
    Type: Application
    Filed: June 22, 2015
    Publication date: June 8, 2017
    Inventors: Frederic TANGY, Anavaj SHAKUNTABAI, Etienne SIMON-LORIERE, Claude ROTH, Philippe BUCHY
  • LENTIVIRUS PSEUDOTYPED WITH INFLUENZA HEMAGGLUTININ AND METHODS OF USE
    Publication number: 20100137412
    Abstract: Highly effective pseudotyping of lentiviral vector with influenza HA, NA and M2 packaging gene constructs at the proper ratios. Lentivirus vector pseudotyped with influenza HA, especially pseudotyped with H5 and neuraminidase. Methods of inducing immune responses to influenza antigens or for transducing genes into cells to which influenza antigens bind using such lentivirus vectors. Methods for screening drugs which inhibit influenza infection using lentivirus pseudotyped with HA.
    Type: Application
    Filed: June 29, 2009
    Publication date: June 3, 2010
    Applicant: INSTITUT PASTEUR OF SHANGHAI
    Inventors: Paul ZHOU, Cheguo Tsai, Tetsuya Toyoda, Philippe Buchy